Dr. Vincent Puard is a skilled professional in the field of biology, with a PhD from the CHRU Bretonneau and INRA Tours and a master's degree in biomedicines from the University of Tours. He also completed a Marie Curie-funded post-doctoral fellowship at Avacta Life Sciences, a UK-based biotech firm working on the development of biomolecules for therapeutic purposes. Currently, Dr. Puard is the co-founder and CEO of MAbSilico, a company that focuses on the development of antibodies and alternative scaffolds for the antibody development market. He has been working at the Luxembourg Institute of Health since 2018, where he has been involved in building a protein chip platform and identifying protein biomarkers for various types of cancer. Dr. Puard has a strong background in antibody development and has utilized his knowledge to investigate various approaches using antibodies and alternative scaffolds. He has also received training in business creation and management through MOOCs organized by HEC and startup incubators. Overall, Dr. Puard has extensive knowledge in the field of biology, with a focus on antibody development and identifying protein biomarkers for cancer. His expertise and experience have enabled him to successfully lead MAbSilico and work on the development of innovative biomolecules for therapeutic purposes.